Get to know our clinical trials

Clinical trial to evaluate the efficacy and safety of the TAR-210 erdafitinib intravesical delivery system compared with intravesical chemotherapy as monotherapy in patients with non-muscle-invasive bladder cancer

THE MAIN OBJECTIVE OF THIS STUDY IS TO COMPARE DISEASE-FREE SURVIVAL (DFS) BETWEEN PATIENTS RECEIVING TAR-210 AND INVESTIGATOR-SELECTED INTRAVESICAL CHEMOTHERAPY.

Imagen del Dr. Felipe Villacampa, urólogo de la Clínica Universidad de Navarra. Dedicación preferencial a la Urooncología, especialmente tumores de vejiga, riñón y testículo. Fertilidad masculina.
Dr. Felipe Villacampa Curriculum
Specialist Urology Department
Madrid headquarters
Cancer Center
Urological Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE III RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM COMPARED WITH INTRAVESICAL CHEMOTHERAPY AS MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (IR-NMIBC) AND SUSCEPTIBLE FGFR ALTERATIONS
  • Code EudraCT: 2023-507684-19
  • Protocol number: 42756493BLC3004
  • Promoter: Janssen Research & Development

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION